GSK seeks approval for Breo in asthma; Pfizer under fire for event spending;

> GlaxoSmithKline ($GSK) and partner Theravance ($THRX) have U.S. approval to market Breo Ellipta for patients with asthma. Report

> AstraZeneca ($AZN) has filed a lawsuit against Mylan ($MYL) in the U.S. to block a generic version of diabetes drug Onglyza. More

> Bayer has named three employees to new U.S. government relations and external communications roles. Release

> Argentina has approved Sanofi's ($SNY) Lemtrada to treat for multiple sclerosis. Release

> Astellas has appointed Tatjana Dragovic as its VP and regional compliance officer for its Americas region. Report 

> ANI Pharmaceuticals has acquired Lithobid Extended Release tablets from Noven Therapeutics. Release

> The FDA has updated the label of NPS Pharmaceuticals' sole product, Gattex. More

And Finally... Pfizer ($PFE) has agreed to pay a $5,000 fine for failing to report spending on a reception it hosted during the 2012 Democratic National Convention. Story